Coinfection with high doses of rVV-p53 (2 × 107 pfu) with a low dose of a recombinant rVV-mIL12 (10 pfu) resulted in a strong tumor inhibition with an increase in the immune response after intratumoral injection in a nude mouse glioma model [71]. This evidence concerns the gene TP53 and central nervous system cancer.